Other languages Edesa Biotech, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
4.632 ^USD	+1.70%		+4.81%	+1.37%

03-05	Top Premarket Gainers	MT
02-09	Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Top Premarket Gainers	03-05
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-09
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-15
Top Premarket Decliners	12-13
Top Premarket Gainers	11-22
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	11-20
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	23-10-25
Top Premarket Decliners	23-10-13
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12
Sector Update: Health Care	23-10-12
Top Midday Gainers	23-10-12
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	23-10-12
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	23-10-10
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	23-09-28
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-09
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	23-06-28
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	23-03-16
Edesa Biotech, US FDA Agree on EB05 Phase 3 Trial's Primary Endpoint, Population	23-03-15
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study	23-03-15

No results for this search